default author photo

Neal E. Ready

Duke University - Duke Cancer Institute

100 Fuqua Drive

Durham, NC 27708-0204

United States

  • Duke University - Duke Cancer Institute

SCHOLARLY PAPERS

1

DOWNLOADS

24

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

The TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer

Number of pages: 30 Posted: 24 Nov 2025
Neal E. Ready, Luis Paz Ares, Kenneth O'Byrne, Melissa Johnson, Martin Reck, Nicolas Girard, Hidetoshi Hayashi, Caicun Zhou, Vishwanath Suresh Gharpure, Radhika Pisupati and Misena Pacius
Duke University - Duke Cancer Institute, University Hospital 12 de Octubre, Queensland University of Technology, Sarah Cannon Research Institute, German Centre for Lung Research - Lungen Clinic Grosshansdorf, PSL Research University - Institut Curie, Kindai University, Tongji University - Department of Medical Oncology, Bristol Myers Squibb, Bristol Myers Squibb and Bristol Myers Squibb
Downloads 24 (1,399,036)

Abstract:

Loading...

Nivolumab, atigotatug, extensive-stage small cell lung cancer, innate immune inducer, Fuc-GM1